Clinical trials: Metastatic Breast Carcinoma
Recurrent or Metastatic Breast Cancer
Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of…
- Trial name
- NCT03109249
- Testing
- SPARC1613, Reference1613
- Where
- 24 sites in India
- Volunteers
- 142 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Metastatic Breast Cancer
Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients
to evaluate whether bone marker can provide the valuable predictor of skeletal complications and whether regular assessing of NTX(N-telopeptide of type I collagen) and osteocalcin can be useful in advanced breast cancer patients…
- Trial name
- NCT00912938
- Testing
- zoledronic acid
- Where
- South Korea
- Volunteers
- 237 people
- Sponsor
- Korean Breast Cancer Study Group
Ovarian Neoplasms, Breast Neoplasms
Establishment of a Tumor Bank for Blood Samples
Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia
- Trial name
- NCT01763125
- Testing
- Blood collection
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Metastatic Breast Cancer
Eribulin in Brain Metastases From HER2-negative Breast Cancer
To evaluate the efficacy of eribulin for treatment of HER2-negative breast cancer brain metastases (BCBM)
- Trial name
- ERIBRAIN (NCT03637868)
- Testing
- Eribulin
- Where
- 7 sites in France
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study on the Efficacy and Safety of IPyC for HER2+ MBC
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity.
- Trial name
- NCT06990347
- Testing
- Inetetamab and Pyrotinib Combined with Chemotherapy
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Fujian Medical University
Breast Cancer
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
This is a Phase II single-arm study designed to evaluate the efficacy and safety of Sac-TMT + KL-A167 in 35 patients with PD-L1+, HR+/HER2- metastatic breast cancer who previously treated with CDK4/6 inhibitor.
- Trial name
- NCT07258108
- Testing
- Lucanisatuzumab plus tagolimumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Metastatic Breast Cancer
Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer
This is a feasibility study to demonstrate the team's ability to collect bone marrow aspirates and biopsies for research purposes from women with metastatic breast cancer.
- Trial name
- NCT01975597
- Testing
- Bone marrow aspirates and biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body.
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT00376688
- Testing
- Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
- Trial name
- CARTIER (NCT03711110)
- Testing
- Intensive cardiovascular monitoring, No intervention
- Where
- 14 sites in Spain
- Volunteers
- 514 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Breast Cancer (Advanced/Metastatic)
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
This is a Phase II, single-arm, Bayesian adaptive trial. The study employs a two-stage design with an interim analysis after 30 evaluable patients and a maximum enrolment of 60 patients.
- Trial name
- HERBRAIN (NCT07905313)
- Testing
- SRS/fSRT+T-Dxd
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Metastatic or Locally Advanced Breast Cancer
Trastuzumab Optimization Trial in Breast Cancer
This is an open-label, randomised phase III, multicentre, Italian study designed to investigate the role of trastuzumab in patients with locally advanced and/or metastatic breast cancer over expressing HER2 who received a first…
- Trial name
- TOP (NCT00637325)
- Testing
- trastuzumab
- Where
- 25 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Regione Lombardia
Metastatic Breast Cancer
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
One important approach to change the natural history of advanced breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of…
- Trial name
- NCT00367250
- Testing
- Cetuximab, Trastuzumab
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Breast Cancer, Metastatic Breast Cancer
Feasibility of Fasting & Exercise in Pts With HR+ MBC
This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine…
- Trial name
- NCT04708860
- Testing
- Prolonged Nightly Fasting, Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of docetaxel or…
- Trial name
- NCT00006120
- Testing
- docetaxel, paclitaxel
- Where
- 35 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with…
- Trial name
- CARMEN-BT01 (NCT04659603)
- Testing
- tusamitamab ravtansine, Gemcitabine
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Breast Neoplasms, Endocrine Breast Diseases
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
About a third of patients with breast cancer are usually treated by hormone pills called tamoxifen and aromatase inhibitors. Aromatase inhibitors are drugs that stop female hormone production.
- Conditions
- Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
- Trial name
- NCT01499160
- Testing
- letrozole, lapatinib, everolimus
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
- Trial name
- CYCAD-1 (NCT06188520)
- Testing
- AZD8421, Camizestrant, Ribociclib
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Advanced Breast Cancer
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
IMPORTANT study is a multicenter, open-label, prospective, randomized-controlled, non-inferiority trial with a pragmatic approach involving older patients (≥ 70 years old) with advanced hormone receptor (HR)-positive/human…
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity
- Trial name
- IMPORTANT (NCT06044623)
- Testing
- CDK 4/6 inhibitors, Endocrine therapy
- Where
- 12 sites in Finland, Greece and 4 more
- Volunteers
- 495 people
- Sponsor
- Region Örebro County
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.